- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04657536
Evaluating the Efficacy of Temperature-controlled Radiofrequency (TRF) in the Treatment of Vulvovaginal Atrophy.
March 19, 2021 updated by: Zhaolijun, Peking University People's Hospital
Randomized Multicenter Clinical Trial for Evaluating the Efficacy of Temperature-controlled Radiofrequency Compared With Topical Estriol in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women
This project will be a prospective, multicenter, randomized cohort study.
The investigators will select patients with vulvovaginal atrophy who have indications for treatment, and set up the experimental group (Peninsula temperature-controlled radiofrequency therapeutic apparatus group) and the control group (promestriene vaginal soft capsules group).
Changes in vaginal exfoliated cell maturity index (MV), score of vaginal symptoms and signs, vaginal health index score (VHIS), female sexual function index score (FSFI), visual analogue score (VAS) before and after treatment, and adverse effects will be observed to analyze the safety and efficacy of temperature-controlled radiofrequency therapy for vulvovaginal atrophy in postmenopausal women.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lijun Zhao, Dr.
- Phone Number: 0086-10-88324384
- Email: lilyzhaopku@163.com
Study Locations
-
-
Beijing
-
Peking, Beijing, China, 100044
- Recruiting
- Peking University People's University
-
Contact:
- Lijun Zhao, Dr.
- Email: lilyzhaopku@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
38 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Menopausal time at least one year.
- Genitourinary Syndrome of Menopause (GSM) related symptoms with moderate or severe intensity, such as dryness and dyspareunia, etc.
- Blood FSH≥30 IU/L (30mIU/mL)。
- Clinical symptoms and signs of vaginal atrophy score≥15.
- Breast ultrasound examination was grade 1-3 within 9 months before the study.
- Voluntary participation in clinical trials and signed informed consent.
- Patients followed the treatment regimen and completed the study.
Exclusion Criteria (one of the following criteria is excluded) :
- The patients who did not meet the inclusion criteria
- Received Estrogen replacement therapy (including local and systemic medication) within 3 months.
- Received any medicine (such as Baofukang suppository) to treat vulvovaginal atrophy within 3 months.
- Corticosteroids were used within 6 weeks. Long-term corticosteroids were used (intermittent nasal or skin application, eye drops and ears are allowed).
- Other experimental drugs were used within 1 month.
- Received vaginal laser therapy within 6 months.
- Patients with acute urinary tract infection;
- Patients with acute genital tract infection (genital herpes, trichomonad, fungal vaginitis; gonococcus, mycoplasma, chlamydia infection and bacterial vaginosis, etc.);
- Patients with pelvic organ prolapse greater than or equal to stage II;
- Patients with metal intrauterine device (IUD);
- Patients with precancerous lesions or malignant tumors of vagina and cervix;
- Patients with serious heart, liver, brain, kidney, endocrine diseases, etc.
- Allergic to control drug and excipients.
- Other malignancies are known or suspected.
- With estrogen-dependent neoplasm.
- Confirm a history of depression or serious mental illness.
- There were consciousness barriers and communication barriers that could not cooperate with the experiment.
- Patients considered unsuitable for this clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TRF group
the group who treated with temperature controlled radiofrequency
|
All subjects will be carried out with 3 standard protocol TRF treatments to the vulvovaginal tissue using the high frequency fulguration equipment (Shenzhen Peninsula Medical co., Ltd) at 10-day to 15-day intervals.
Radiofrequency energy was applied to the vaginal canal through a specialized probe combining monopolar and bipolar treatment modes.
Monopolar treatment mode is for 15 minutes.
Aim the three indication points A, B and C on the probe to the direction of 12 o'clock in turn.
Each area should be treated for about 5 minutes.
Rotate the probe clockwise when changing the area for treatment.Bipolar treatment mode is for 10 minutes.
Firstly, indication point A is aimed to 12 o'clock for 5-minutes treatment and then the probe is rotated 90°clockwise for another 5-minutes treatment.
The power setting will be 35-40w, and the target temperature setting will be 40 to 45℃, titrated to subject tolerance.
Other Names:
|
Active Comparator: Estriol group
the group who treated with promestriene vaginal soft capsules
|
Promestriene vaginal soft capsules(Zhejiang Anbao Pharmaceutical Co. LTD)will be used 10mg once a day for continuous 20 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change value of vaginal maturation index (VMI) compared with baseline
Time Frame: The two groups will be visited on day 0, 1 month and 3 months after the last treatment.
|
The Vaginal Maturation Index (VMI) is an assessment done to establish the oestrogen effect in the body.
The vaginal cytology specimens were collected from the mid-vaginal-wall before treatment and fixed in ThinPrep solution.
The VMI is a ratio obtained with three main cell types found in the vaginal walls: parabasal cells(P), Intermediate cells (I) and superficial cells(S).
The findings will be presented in a 0/0/0 format.
VMI = [1 × (% superficial cells)] + [0.6 × (% intermediate cells)] + [0.2 × (% parabasal cells)].
This index enabled us to objectively evaluate the differential count of each cell group expressed as a percentage.
The greater the degree of vaginal atrophy, the greater the estrogen deficiency.
When at most 30% of the deep cells were present in the vaginal smears, mild hypoestrogenism was diagnosed.
A deep cell percentage between 30% and 49% indicated moderate hypoestrogenism and a more than 50% deep cell percentage indicated hypoestrogenism.
|
The two groups will be visited on day 0, 1 month and 3 months after the last treatment.
|
the changes of vaginal symptoms and signs scores compared with baseline
Time Frame: The two groups will be visited on day 0, day 20(the control group is day 21),1 month and 3 months after the last treatment.
|
Symptoms (vaginal dryness, pruritus, burning, pain, shallow dyspareunia, deep dyspareunia) will be individually scored by women and signs (vaginal mucosa and petechia, vaginal elasticity, mucosal luster) will be individually scored by the investigators as 0 = absence, 1 = mild, 2 = moderate, and 3 = severe alteration.
In addition, a composite score of symptoms and signs will calculated by the addition of the intensity scores of all individual symptoms and signs (range, 0-27: The higher the score is, the more severe the genitourinary atrophy is.).
Symptoms and signs score (SSC) will be obtained at each visiting to assess the effect of treatment on all individual.
|
The two groups will be visited on day 0, day 20(the control group is day 21),1 month and 3 months after the last treatment.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The changes of vaginal health index score (VHI) compared with baseline
Time Frame: The two groups will be visited on day 0, day 20(the control group is day 21),1 month and 3 months after the last treatment.
|
VHI scores accounted for the following five parameters: elasticity, fluid volume, pH, epithelial integrity, and moisture.
Each parameter will be graded from 1 (worst condition) to 5 (best condition) with a maximum possible score of 25 points.
Scores less than 15 are indicative of vaginal atrophy.
|
The two groups will be visited on day 0, day 20(the control group is day 21),1 month and 3 months after the last treatment.
|
The changes of female sexual function index score (FSFI) compared with baseline
Time Frame: The two groups will be visited on day 0, 1 month and 3 months after the last treatment.
|
Sexual function will be measured using the Female Sexual Function Index (FSFI).
This questionnaire, which contains 19 items, was developed as a brief, but multidimensional, self-reporting instrument to assess the key dimensions of female sexual function.
It was developed based on a group of normal female controls and age-matched women who met the DSM-IV-TR criteria for female sexual arousal disorder (FSAD).
The FSFI addresses six domains of sexual function (desire, arousal, lubrication, orgasm, satisfaction, and pain) and provides full-scale scores ranging from 2.0 (severe dysfunction) to 36.0 (absence of dysfunction).
The validated FSFI version for the Chinese language will be used.
A cutoff score of 26.55 will be used to differentiate the presence or absence of sexual dysfunction.
|
The two groups will be visited on day 0, 1 month and 3 months after the last treatment.
|
The changes of visual analogue score (VAS) compared with baseline
Time Frame: The two groups will be visited on day 0, day 20(the control group is day 21),1 month and 3 months after the last treatment.
|
The Visual Analogue Scale (VAS) is a popular tool for the measurement of pain.
The pain is represented by 11 Numbers from 0 to 10, 0 is painless and 10 is the most painful.
The patient chooses one of these 11 Numbers to represent the pain level according to her own pain level.
|
The two groups will be visited on day 0, day 20(the control group is day 21),1 month and 3 months after the last treatment.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 8, 2020
Primary Completion (Anticipated)
December 1, 2021
Study Completion (Anticipated)
December 1, 2021
Study Registration Dates
First Submitted
October 8, 2020
First Submitted That Met QC Criteria
December 1, 2020
First Posted (Actual)
December 8, 2020
Study Record Updates
Last Update Posted (Actual)
March 22, 2021
Last Update Submitted That Met QC Criteria
March 19, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Version 2.0;20200221
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postmenopausal Vulvovaginal Atrophy
-
Lee's Pharmaceutical LimitedActive, not recruitingPostmenopausal Vulvovaginal AtrophyChina
-
Warner ChilcottCompletedPostmenopausal Vulvovaginal AtrophyUnited States
-
Nathura S.p.AEvidilya S.r.l.Recruiting
-
Koru Health GroupsCompletedVulvovaginal AtrophyTurkey
-
MadorraCompletedVulvovaginal AtrophyAustralia
-
Warner ChilcottCompletedVulvovaginal AtrophyUnited States
-
El. En. SpAStanford University; The Christ HospitalCompletedVulvovaginal AtrophyUnited States
-
PepTonic Medical ABCompletedVulvovaginal AtrophySweden
-
Faculdade de Medicina do ABCCompleted
-
University of MessinaUniversity of Victoria; University of AthensCompletedMenopause | Vulvovaginal Atrophy
Clinical Trials on high frequency fulguration equipment
-
Centro Universitario La SalleCompletedChronic Pain | Neck Pain | Myofascial Pain SyndromeSpain
-
Sahmyook UniversityCompletedPrimary Dysmenorrhea | DysmucorrheaKorea, Republic of
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedRespiratory Distress Syndrome, AdultUnited States
-
University of California, San FranciscoRecruitingPain, Postoperative | Complex Regional Pain Syndromes | Spinal Cord Injuries | Nerve Injury | Trigeminal Neuralgia | Post-herpetic Neuralgia | Post-Stroke Pain | Nerve Root Avulsion | Chronic Neuropathic PainUnited States
-
Seoul National University Bundang HospitalCompletedStroke | AphasiaKorea, Republic of
-
Meshalkin Research Institute of Pathology of CirculationCompletedChronic Limb-Threatening IschemiaRussian Federation
-
University of BirminghamMaastricht UniversityCompletedPhysical ActivityUnited Kingdom
-
Fred Hutchinson Cancer CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
The Center for Clinical Research, Winston-Salem...CompletedLow Back Pain | Chronic Pain | Radiculopathy | Complex Regional Pain Syndrome (CRPS)United States